Journal article

Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20( ) lymphoid malignancies

Andrew W Roberts, Ranjana H Advani, Brad S Kahl, Daniel Persky, John W Sweetenham, Dennis A Carney, Jianning Yang, Todd B Busman, Sari H Enschede, Roderick A Humerickhouse, John F Seymour

British Journal of Haematology | WILEY | Published : 2015

Grants

Awarded by National Health and Medical Research Council of Australia


Funding Acknowledgements

We thank the trial staff and referring physicians at each of the trial sites and the patients and their families who made this study possible. Julie Dziubinski, Lura Morris, Min Tian and Joseph Beason are thanked for operational support, and Michael Brune and Teresa McNally for editorial assistance with the manuscript. All are employees of AbbVie Inc. Andrew W. Roberts has received research funding from AbbVie and Genentech and is an employee of Walter and Eliza Hall Institute of Medical Research, which receives milestone payments related to ABT-199. Ranjana H. Advani has received research funding from Genentech, is an unpaid advisor to Genentech, and her institution has received research funding from AbbVie. Brad Kahl has received research funding from AbbVie and Genentech, and is a consultant for Genentech. Daniel Persky and Dennis A. Carney have no conflicts to disclose. John W. Sweetenham indicates that his institution has received research funding from AbbVie. John F. Seymour is a consultant to and advisory board member for Roche and Genentech. Jianning Yang, Todd Busman, Sari H. Enschede, and Roderick A. Humerickhouse are AbbVie employees and may hold stock. This study was funded by AbbVie and Genentech, Inc. AWR's research was supported by the National Health and Medical Research Council of Australia (637309, 1016647, 461219), the Victorian Cancer Agency, the Australian Cancer Research Foundation, and the Leukemia and Lymphoma Society.